An Arizona doctor’s perspective on Theranos
Theranos is dealing with more push-back as its finger-stick blood-testing method gets put on hold at Walgreens locations before the FDA gives a final OK.
Theranos is dealing with more push-back as its finger-stick blood-testing method gets put on hold at Walgreens locations before the FDA gives a final OK.
It looks like stealth startup SalveoDx is developing technology in the single drop of blood diagnostics space - a field dominated by Theranos to date. The company just raised $2 million.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Palo Alto super-startup Theranos got the OK from the FDA for its HSV-1 test to be performed outside of CLIA-certified labs - an important cog in its marketing strategy.
Theranos, the secretive Palo Alto diagnostics company, just received regulatory approval for its HSV-1 test - a sign that perhaps it'll start chasing further approvals.